



NATCO PHARMA LIMITED

Statement of stand-alone Financial Results for the quarter and half year ended 30th September 2015

Rs. in lakhs

PART I : STATEMENT OF STAND-ALONE FINANCIAL RESULTS PARTICULARS	THREE MONTHS ENDED (REVIEWED/UN-AUDITED)			YEAR-TO-DATE FIGURES FOR THE HALF YEAR ENDED ON (REVIEWED/UN-AUDITED)		YEAR ENDED (AUDITED)
	30 September 2015	30 June 2015	30 September 2014	30 September 2015	30 September 2014	31 March 2015
	01. Gross Sales/Income from Operations	20,435	19,699	18,677	40,134	35,627
Less: Excise Duty	809	530	215	1,339	557	1,143
Less: Sales Tax	635	552	351	1,187	759	1,571
<b>Net Sales/Income from Operations</b>	<b>18,991</b>	<b>18,617</b>	<b>18,111</b>	<b>37,608</b>	<b>34,311</b>	<b>66,450</b>
02. Other Operating Income	1,213	788	1,017	2,001	2,965	5,107
<b>03. TOTAL INCOME FROM OPERATIONS</b>	<b>20,204</b>	<b>19,405</b>	<b>19,128</b>	<b>39,609</b>	<b>37,276</b>	<b>71,557</b>
<b>04. EXPENDITURE</b>						
a) Cost of materials consumed	6,376	6,181	3,820	12,557	7,712	17,858
b) Purchases of stock-in-trade	-	37	-	37	-	88
c) Changes in inventories of finished goods, work-in progress and stock-in-trade	(1,838)	(1,025)	725	(2,863)	1,202	(876)
d) Employee benefits expense	3,551	3,464	2,909	7,015	5,624	11,619
e) Depreciation and amortization expense	1,124	1,120	1,023	2,244	2,042	4,246
f) Other Expenses	6,037	4,693	5,586	10,730	10,594	20,010
<b>TOTAL EXPENSES</b>	<b>15,250</b>	<b>14,470</b>	<b>14,063</b>	<b>29,720</b>	<b>27,174</b>	<b>52,945</b>
<b>05. Profit/(Loss) from Operations before other income, finance costs and exceptional items</b>	<b>4,954</b>	<b>4,935</b>	<b>5,065</b>	<b>9,889</b>	<b>10,102</b>	<b>18,612</b>
06. Other Income	308	283	300	591	388	1,355
<b>07. Profit/(Loss) from ordinary activities before finance Cost and exceptional items</b>	<b>5,262</b>	<b>5,218</b>	<b>5,365</b>	<b>10,480</b>	<b>10,490</b>	<b>19,967</b>
08. Finance costs	754	777	699	1,531	1,335	3,013
<b>09. Profit/(Loss) from ordinary activities after finance Costs but before exceptional items</b>	<b>4,508</b>	<b>4,441</b>	<b>4,666</b>	<b>8,949</b>	<b>9,155</b>	<b>16,954</b>
10. Exceptional Item	-	-	-	-	-	1,513
<b>11. Profit/(Loss) from ordinary activities before tax</b>	<b>4,508</b>	<b>4,441</b>	<b>4,666</b>	<b>8,949</b>	<b>9,155</b>	<b>15,441</b>
12. Current Tax expense	962	948	991	1,910	1,932	3,252
13. Deferred Tax expense /(reversal)	86	86	195	172	102	(3,103)
<b>14. Net Profit/(Loss) from ordinary activities after tax</b>	<b>3,460</b>	<b>3,407</b>	<b>3,480</b>	<b>6,867</b>	<b>7,121</b>	<b>15,292</b>
15. Extraordinary items (net of tax expenses)	-	-	-	-	-	-
<b>16. Net Profit/(Loss) for the period</b>	<b>3,460</b>	<b>3,407</b>	<b>3,480</b>	<b>6,867</b>	<b>7,121</b>	<b>15,292</b>
17. Paid-up Equity Share Capital (each share of Rs.10/-face value)	3,483	3,323	3,307	3,483	3,307	3,323
18. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year	-	-	-	-	-	84,576
<b>19. Earnings per share</b>	<b>10.35</b>	<b>10.25</b>	<b>10.52</b>	<b>20.60</b>	<b>21.53</b>	<b>46.17</b>
Basic and diluted EPS before and after extraordinary item (Rs.) – non-annualized	10.35	10.25	10.52	20.60	21.53	46.17
<b>PART II : SELECT INFORMATION</b>						
20. Public Share holding :						
a) Number of Shares	1,69,68,985	1,53,68,985	1,53,73,943	1,69,68,985	15373943	1,53,73,985
b) Percentage of Share holding	48.71	46.24	46.48	48.71	46.48	46.26
21. Promoters and Promoter Group Shareholding						
a) Pledged/Encumbered – No.of shares	-	-	-	-	-	-
b) Non-encumbered–No.of shares	1,78,65,864	1,78,65,864	1,76,99,131	1,78,65,864	1,76,99,131	1,78,60,864
Percentage (as a % of the total share holding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
Percentage (as a % of the total share capital of the company)	51.29	53.76	53.52	51.29	53.52	53.74

Dated at Hyderabad, this, the 13th day of November, 2015.  
for and on behalf of the Board of Directors,  
NATCO Pharma Limited

V. C. Nannapaneni  
Chairman & Managing Director

Pending as on 01-07-2015	-
Received during the quarter	124
Resolved during the quarter	124
Pending as on 30-09-2015	-



NATCO PHARMA LIMITED

Statement of consolidated Financial Results for the quarter and half year ended 30th September 2015

Rs.in lakhs

PART I : STATEMENT OF CONSOLIDATED RESULTS PARTICULARS	THREE MONTHS ENDED (UN-REVIEWED/UN-AUDITED)			YEAR-TO-DATE FIGURES FOR THE HALF YEAR ENDED ON (UN-REVIEWED/UN-AUDITED)		YEAR ENDED (AUDITED)
	30 September 2015	30 June 2015	30 September 2014	30 September 2015	30 September 2014	31 March 2015
01. Gross Sales/Income from Operations	23,730	22,745	21,532	46,475	41,341	80,306
Less: Excise Duty	812	531	267	1,343	633	1,295
Less: Sales Tax	641	645	359	1,286	772	1,591
<b>Net Sales/Income from Operations</b>	<b>22,277</b>	<b>21,569</b>	<b>20,906</b>	<b>43,846</b>	<b>39,936</b>	<b>77,420</b>
02. Other Operating Income	1,213	802	1,017	2,015	2,965	5,107
<b>03. TOTAL INCOME FROM OPERATIONS</b>	<b>23,490</b>	<b>22,371</b>	<b>21,923</b>	<b>45,861</b>	<b>42,901</b>	<b>82,527</b>
<b>04. EXPENDITURE</b>						
a) Cost of materials consumed	6,240	5,744	5,716	11,984	11,779	16,726
b) Purchases of stock-in-trade	2,315	2,388	-	4,703	-	8,428
c) Changes in inventories of finished goods, work-in progress and stock-in-trade	(1,819)	(1,148)	725	(2,967)	1,202	(917)
d) Employee benefits expense	4,304	4,026	3,368	8,330	6,525	13,692
e) Depreciation and amortization expense	1,268	1,264	1,115	2,532	2,228	4,726
f) Other Expenses	6,601	5,615	6,229	12,216	11,760	23,261
<b>TOTAL EXPENSES</b>	<b>18,909</b>	<b>17,889</b>	<b>17,153</b>	<b>36,798</b>	<b>33,494</b>	<b>65,916</b>
<b>05. Profit/(Loss) from Operations before other income, finance costs and exceptional items</b>	<b>4,581</b>	<b>4,482</b>	<b>4,770</b>	<b>9,063</b>	<b>9,407</b>	<b>16,611</b>
06. Other Income	207	183	319	390	437	1,491
<b>07. Profit/(Loss) from ordinary activities before finance Cost and exceptional items</b>	<b>4,788</b>	<b>4,665</b>	<b>5,089</b>	<b>9,453</b>	<b>9,844</b>	<b>18,102</b>
08. Finance costs	766	808	724	1,574	1,380	3,168
<b>09. Profit/(Loss) from ordinary activities after finance Costs but before exceptional items</b>	<b>4,022</b>	<b>3,857</b>	<b>4,365</b>	<b>7,879</b>	<b>8,464</b>	<b>14,934</b>
10. Exceptional Item	-	-	-	-	-	1,513
<b>11. Profit/(Loss) from ordinary activities before tax</b>	<b>4,022</b>	<b>3,857</b>	<b>4,365</b>	<b>7,879</b>	<b>8,464</b>	<b>13,421</b>
12. Current Tax expense	1,018	1,017	1,241	2,035	2,119	3,512
13. Deferred Tax expense /(Reversal)	86	86	-	172	-	(3,117)
<b>14. Net Profit/ (Loss) from ordinary activities after tax</b>	<b>2,918</b>	<b>2,754</b>	<b>3,124</b>	<b>5,672</b>	<b>6,345</b>	<b>13,026</b>
15. Minority Interest	(39)	(69)	(113)	(108)	(238)	(435)
<b>16. Net Profit/ (Loss) for the period</b>	<b>2,957</b>	<b>2,823</b>	<b>3,237</b>	<b>5,780</b>	<b>6,583</b>	<b>13,461</b>
17. Paid-up Equity Share Capital(each share of Rs.10/-face value)	3,483	3,323	3,307	3,483	3,307	3,323
18. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year	-	-	-	-	-	81,282
<b>19. Earnings per share</b>						
Basic and diluted EPS before and after extraordinary item (Rs.) – non-annualized	8.84	8.50	9.79	17.34	19.91	40.64
	8.84	8.50	9.79	17.34	19.91	40.64
<b>PART II : SELECT INFORMATION</b>						
20. Public Share holding :						
a) Number of Shares	1,69,68,985	1,53,68,985	1,53,73,943	1,69,68,985	153,73,943	1,53,73,985
b) Percentage of Share holding	48.71	46.24	46.48	48.71	46.48	46.26
21. Promoters and Promoter Group Shareholding						
a) Pledged/Encumbered – No. of shares	-	-	-	-	0	-
b) Non-encumbered–No. of shares	1,78,65,864	1,78,65,864	1,76,99,131	1,78,65,864	1,76,99,131	1,78,60,864
Percentage (as a % of the total share holding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
Percentage (as a % of the total share capital of the company)	51.29	53.76	53.52	51.29	53.52	53.74

The above un-audited financial results were reviewed by the Audit Committee, and approved by the Board of Directors at a meeting held at Hyderabad, on Friday, the 13th November, 2015. There are no exceptional and extraordinary items to be reported for the period under review. The stand alone result are available on the company website [www.natcopharma.co.in](http://www.natcopharma.co.in).

Dated at Hyderabad, this, the 13th day of November, 2015.  
for and on behalf of the Board of Directors,  
NATCO Pharma Limited

V. C. Nannapaneni  
Chairman & Managing Director

Pending as on 01-07-2015	-
Received during the quarter	124
Resolved during the quarter	124
Pending as on 30-09-2015	-

Regd. Office: NATCO House, Road # 2, Banjara Hills, Hyderabad : 500 034



NATCO PHARMA LIMITED

Report of segment wise revenue, Results and Capital Employed (Un-audited) under Clause 41 of the Listing Agreement, for the quarter and half year ended on 30th September, 2015

Rs. In lakhs

PARTICULARS	THREE MONTHS ENDED (UN-REVIEWED/UN-AUDITED)			HALF YEAR ENDED (UN-REVIEWED/UN-AUDITED)		PREVIOUS ACCOUNTING YEAR ENDED (UN-AUDITED)
	30-Sep-15	30-Jun-15	30-Sep-14	30-Sep-15	30-Sep-14	31-Mar-15
<b>01. Segment Revenue(Net)</b>						
a) Bulk Chemicals	5,198	5,580	7,431	10,778	15,958	29,468
b) Formulations	15,910	14,146	11,882	30,056	20,848	42,524
c) Job Work	127	221	206	348	436	830
d) Unallocated	31	326	240	357	1,210	2,502
<b>Total</b>	<b>21,266</b>	<b>20,273</b>	<b>19,759</b>	<b>41,539</b>	<b>38,452</b>	<b>75,324</b>
Less: Inter-Segment Revenue	1,062	868	631	1,930	1,176	3,767
<b>Net Sales/Income from Operations</b>	<b>20,204</b>	<b>19,405</b>	<b>19,128</b>	<b>39,609</b>	<b>37,276</b>	<b>71,557</b>
<b>02. Segment Results: Profit(+)/Loss(-) before tax and interest</b>						
a) Bulk Chemicals	495	1,134	761	1,629	4,718	8,043
b) Formulations	6,781	5,712	6,579	12,493	9,647	17,784
c) Job Work	108	190	178	298	361	684
d) Unallocated	77	243	41	320	94	1,354
<b>Total</b>	<b>7,461</b>	<b>7,279</b>	<b>7,559</b>	<b>14,740</b>	<b>14,820</b>	<b>27,865</b>
Less: a) Interest	754	777	699	1,531	1,335	3,013
b) Other unallocable expenditure	2,507	2,344	2,494	4,851	4,718	10,766
c) Unallocable Income	(308)	(283)	(300)	(591)	(388)	(1,355)
<b>Total Profit Before Tax</b>	<b>4,508</b>	<b>4,441</b>	<b>4,666</b>	<b>8,949</b>	<b>9,155</b>	<b>15,441</b>
<b>03. Capital Employed (Segment Assets- Segment Liabilities)</b>						
a) Bulk Chemicals	47,598	46,963	46,920	47,598	46,920	44,091
b) Formulations	47,164	45,123	40,074	47,164	40,074	44,740
c) Job Work	41	101	173	41	173	227
d) Unallocated (Others)	33,408	(881)	(7,170)	33,408	(7,170)	(1,159)
<b>Total</b>	<b>1,28,211</b>	<b>91,306</b>	<b>79,997</b>	<b>1,28,211</b>	<b>79,997</b>	<b>87,899</b>

The above un-audited financial results were reviewed by the Audit Committee, Statutory Auditors and approved by the Board of Directors at a meeting held at Hyderabad, on Friday, the 13th November, 2015. Figures for the previous period(s) have been re-arranged / re-grouped wherever necessary.

The Company has allotted 1,600,000 equity shares of Rs.10 each at a premium of Rs.2,120.55 per equity share on 18 September 2015 pursuant to a Qualified Institutions Placement under Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 (as amended). Share issue expenses amounting to Rs.642 lakhs have been adjusted against the Securities Premium Account in terms of the provisions of Section 52 of the Companies Act, 2013 instead of charging to Statement of Profit and Loss account as done earlier.

As at 30 September 2015, Short term loans and advances includes term deposits with financial institutions amounting to ₹4,000 lakhs.

Dated at Hyderabad, this, the 13th day of November, 2015.

for and on behalf of the Board of Directors,  
NATCO Pharma Limited

**V. C. Nannapaneni**  
Chairman & Managing Director

Regd. Office: NATCO House, Road # 2, Banjara Hills, Hyderabad : 500 034



NATCO PHARMA LIMITED

STATEMENT OF STAND-ALONE ASSETS AND LIABILITIES

Rs. In lakhs

Particulars	As at 30-Sep-2015 (Reviewed/Unaudited)	As at 31-Mar-2015 (Audited)
<b>Equity &amp; Liabilities</b>		
<b>Shareholders' Funds</b>		
a) Share Capital	3,483	3,323
b) Reserves & Surplus	1,24,728	84,576
<b>Sub-total: Shareholders' Funds</b>	<b>1,28,211</b>	<b>87,899</b>
<b>Non-current liabilities</b>		
a) Long term borrowings	342	9,628
b) Deferred tax liabilities(net)	1,301	1,129
c) Other long-term liabilities	77	77
d) Long term provisions	1,117	919
<b>Sub-total: Non-current Liabilities</b>	<b>2,837</b>	<b>11,753</b>
<b>Current Liabilities</b>		
a) Short term borrowings	10,821	16,854
b) Trade payables	15,890	11,534
c) Other current liabilities	8,692	11,332
d) Short-term provisions	111	111
<b>Sub-total: Current Liabilities</b>	<b>35,514</b>	<b>39,831</b>
<b>TOTAL- EQUITY AND LIABILITIES</b>	<b>1,66,562</b>	<b>1,39,483</b>
<b>Assets</b>		
<b>Non-Current Assets</b>		
a) Fixed Assets		
Tangible Assets	58,112	56,802
Intangible Assets	457	471
b) Capital Work-in-progress	12,932	10,077
c) Non- Current Investments	14,295	13,115
d) Long term loans and advances	15,999	14,247
e) Other non-current assets	367	352
<b>Sub-total: Non-Current Assets</b>	<b>1,02,162</b>	<b>95,064</b>
<b>Current Assets</b>		
a) Current Investments	2,012	12
b) Inventories	24,938	19,835
c) Trade receivables	19,843	18,896
d) Cash and Cash Equivalents	7,485	719
e) Short term loans and advances	9,661	4,766
f) Other Current Assets	461	191
<b>Sub-total: Current Assets</b>	<b>64,400</b>	<b>44,419</b>
<b>TOTAL- ASSETS</b>	<b>1,66,562</b>	<b>1,39,483</b>



NATCO PHARMA LIMITED

STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES

Rs. In Lakhs

Particulars	As at 30-Sep-2015 (Un Reviewed)	As at 31-Mar-2015 (Audited)
<b>Equity and Liabilities</b>		
<b>Shareholders' Funds</b>		
a) Share Capital	3,483	3,323
b) Reserves and Surplus	1,20,348	81,282
<b>Sub-total: Shareholders' funds</b>	<b>1,23,831</b>	<b>84,605</b>
c) Minority Interest	498	503
<b>Non-Current Liabilities</b>		
a) Long term borrowings	359	9,702
b) Deferred tax liabilities (net)	1,361	1,189
c) Other long-term liabilities	77	83
d) Long term provisions	1,152	950
<b>Sub-total: Non-current Liabilities</b>	<b>2,949</b>	<b>11,924</b>
<b>Current Liabilities</b>		
a) Short term borrowings	10,884	16,854
b) Trade payables	17,025	12,530
c) Other current liabilities	9,125	11,856
d) Short-term provisions	116	133
<b>Sub-total: Current Liabilities</b>	<b>37,150</b>	<b>41,373</b>
<b>TOTAL- EQUITY AND LIABILITIES</b>	<b>1,64,428</b>	<b>1,38,405</b>
<b>Assets</b>		
<b>Non-Current Assets</b>		
a) Fixed Assets	-	
Tangible Assets	67,473	66,403
Intangible Assets	4,506	4,595
b) Capital Work-in-progress	15,963	12,896
c) Non- Current Investments	157	157
d) Long term loans and advances	7,222	5,703
e) Other non-current assets	998	354
<b>Sub-total: Non-Current Assets</b>	<b>96,319</b>	<b>90,108</b>
<b>Current Assets</b>		
a) Current Investments	2,012	12
b) Inventories	27,423	22,000
c) Trade receivables	20,340	19,243
d) Cash and Cash Equivalents	7,654	1,336
e) Short term loans and advances	10,153	5,515
f) Other Current Assets	527	191
<b>Sub-total: Current Assets</b>	<b>68,109</b>	<b>48,297</b>
<b>TOTAL- ASSETS</b>	<b>1,64,428</b>	<b>1,38,405</b>